Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
about
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsHuman breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapyNear infrared fluorescent optical imaging for nodal staging.uPAR and HER2 Genes Are Usually Co-Amplified in Individual Breast Cancer Cells from Blood and Tissues.Targeting HER2 in breast cancer: overview of long-term experienceThe Wnt signaling pathway: implications for therapy in osteosarcoma.HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsuPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report.Mechanisms of drug inhibition of signalling molecules.Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials.The ERBB3 receptor in cancer and cancer gene therapyDetermination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.Assessment of free dye in solutions of dual-labeled antibody conjugates for in vivo molecular imaging.Colorectal cancer in review: the role of the EGFR pathway.Imaging of the interaction of cancer cells and the lymphatic system.FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells.The peptide derived from erbB2 auto-inhibitor herstatin shared in the same epitope and function with functional antibody 2C4.Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.Mammary epithelial cells treated concurrently with TGF-alpha and TGF-beta exhibit enhanced proliferation and death.A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma.Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells.Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study.Overcoming trastuzumab resistance with nordihydroguaiaretic acid?The Dawning of Translational Breast Cancer: From Bench to Bedside.Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study.Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease.
P2860
Q26830569-12C94BFB-2BD0-4720-892E-2F45174671E8Q33353929-9523EDB0-BBC5-4D43-9CB6-72EB4AA4247AQ34038991-6D467E0B-9646-4E65-BFCC-BB55A4C361A0Q34095775-DDDCB444-7CEB-4ED2-A9FE-1928244D95BAQ34272044-399D541E-CCE9-40EF-A35E-A83331AB59F4Q34632285-0F4A3303-75A7-4036-B7D6-147FD8B5B556Q35201923-B8BFC363-F359-4692-9EF0-D9C8030197A1Q35720929-9530EE4C-BE8D-4EC0-8BC1-72F833533A58Q35786706-8746DDDB-93EA-4770-846C-7100ECFFA364Q35869998-E9D1C983-AEE3-4989-81D6-0CBB76790D64Q36488752-028FE0D3-BAB7-4F8F-A576-E8F82FE906E9Q36609570-39655C5F-F0D8-4634-BC4A-CECD70974755Q36689038-F47E6836-958A-47C0-A80B-CCE37B57E975Q37135372-AB3BEE37-74CB-4E5C-BB88-35970631898BQ37205574-A5121F69-53C5-4B3E-908C-8F831C6B81AFQ37645745-4D32CE0B-58F6-4EBB-A491-BD787CB8E5A4Q37679938-31FC5FF0-8049-40C0-9784-CB7922598E7FQ37896249-FDCF4BAC-D19B-4919-8668-69917A66D9D3Q38841683-BD0269E4-06D1-4FBA-AB2C-8DDC0F43561FQ38852051-0AE0D0AB-22F8-48E5-B2E9-94D1DFA29075Q38867798-5366D811-B999-4549-8180-8B3EA53DCA68Q39276348-57874EA6-136F-4B60-B4E4-E28D6E9B02AEQ39433244-7DD328CD-9A4A-4A88-B5C6-DD37CD2F3F65Q39455425-8227AD84-76BF-4C56-8DDB-D4F22FA6D949Q39580432-7D8FB696-8553-4033-AE8D-E5128DADD8FDQ40089245-847BDF16-16F3-462D-9F97-914A93981EB8Q40179159-256F6291-A0B4-4C77-9B00-E3E2A7249FB6Q41694289-0FD356EF-2BEA-49B7-8122-0586D83EB5FDQ43635483-F05EB9FF-AD45-4785-94D0-3E426C9D346BQ46829258-9569FB2F-04AD-4380-91F5-4A16AF647F6EQ49544424-4FCB2448-E370-406E-BBEA-D2B3C40BD481Q50687140-33106A7C-F2FF-4163-84EA-F0871A44FE14Q51328222-A4CC985F-3AA0-4EA8-AF1A-A2DEDDF122F2Q54453342-7DC3F16F-1205-40C1-8681-20E5FA72DEE9
P2860
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
@ast
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
@en
type
label
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
@ast
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
@en
prefLabel
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
@ast
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
@en
P2860
P1476
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
@en
P2093
Christina H Yeon
Mark D Pegram
P2860
P2888
P304
P356
10.1007/S10637-005-2899-8
P577
2005-10-01T00:00:00Z